41120-23-4

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for the treatment of different diseases and conditions. Its unique structure and properties contribute to the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical sector, ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate serves as a crucial component in the production of bioactive compounds. These compounds are utilized in the development of pesticides, herbicides, and other agricultural chemicals to enhance crop protection and yield.
Used in Research and Development:
Ethyl 2-oxo-2,3-dihydro-1H-benzo[d]iMidazole-1-carboxylate is employed as a valuable research tool in the field of organic chemistry and medicinal chemistry. Its synthetic utility and potential biological activities make it an attractive candidate for the exploration of novel chemical entities and the advancement of scientific knowledge.

InChI:InChI=1/C10H10N2O3/c1-2-15-10(14)12-8-6-4-3-5-7(8)11-9(12)13/h3-6H,2H2,1H3,(H,11,13)

Upstream product

• 506-68-3 bromocyane 
• 18631-99-7 N-hydroxy-N-phenyl-carbamic acid ethyl ester 
• 615-16-7 1H-benzimidazol-2-ol 
• 161468-57-1 2-oxo-benzoimidazole-1,3-dicarboxylic acid diethyl ester 
• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 7325-39-5 ethyl pyridine-2-yl carbonate 

Downstream Products

• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 161468-70-8 Ethyl 2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazole-1-carboxylate 
• 161468-81-1 2-Oxo-3-(2-oxo-2-phenyl-ethyl)-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161468-80-0 3-(Ethoxycarbonyl-phenyl-methyl)-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161468-52-6 ethyl 6-bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-1-carboxylate 
• 161468-72-0 3-(3,5-Difluoro-benzyl)-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161468-86-6 2-Oxo-3-(toluene-4-sulfonyl)-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161468-71-9 2-Oxo-3-(3-trifluoromethyl-benzyl)-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 339013-51-3 3-(2,6-dichloro-benzyl)-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid ethyl ester 
• 161921-87-5 1-(4-tert-butyldimethylsilyloxy-3-propylphenylmethyl)-3-carboethoxy-2-benzimidazolinone 
• 64928-98-9 1-(2-oxo-propyl)-1,3-dihydro-benzoimidazol-2-one 
• 30770-12-8 1-benzyl-5-bromo-1,3-dihydro-benzoimidazol-2-one 
• 396725-94-3 3-Benzyl-5-bromo-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester 
• 1026498-98-5 3-Benzyl-5-chloro-2-oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [18F]-PET Imaging in a Primate Brain

We report the synthesis of 46 tertiary amine-bearing N-alkylated benzo[d]imidazol-2(3H)-ones, imidazo[4,5-b]pyridin-2(3H)-ones, imidazo[4,5-c]pyridin-2(3H)-ones, benzo[d]oxazol-2(3H)-ones, oxazolo[4,5-b]pyridin-2(3H)-ones and N,N′-dialkylated benzo[d]imidazol-2(3H)-ones. These compounds were evaluated against 5-HT7R, 5-HT2AR, 5-HT1AR, and 5-HT6R as potent dual 5-HT7/5-HT2A serotonin receptors ligands. A thorough study of the structure-activity relationship of the aromatic rings and their substituents, the alkyl chain length and the tertiary amine was conducted. 1-(4-(4-(4-Fluorobenzoyl)piperidin-1-yl)butyl)-1H-benzo[d]imidazol-2(3H)-one (79) and 1-(6-(4-(4-fluorobenzoyl)piperidin-1-yl)hexyl)-1H-benzo[d]imidazol-2(3H)-one (81) were identified as full antagonist ligands on cyclic adenosine monophosphate (cAMP, KB = 4.9 and 5.9 nM, respectively) and inositol monophosphate (IP1, KB = 0.6 and 16 nM, respectively) signaling pathways of 5-HT7R and 5-HT2AR. Both antagonists crossed the blood-brain barrier as evaluated with [18F] radiolabeled compounds [18F]79 and [18F]81 in a primate's central nervous system using positron emission tomography. Both radioligands showed standard uptake values ranging from 0.8 to 1.1, a good plasmatic stability, and a distribution consistent with 5-HT7R and 5-HT2AR in the CNS.

SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE

The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.

BENZIMIDAZOLINONES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES

Phenoxyphenylacetic acids and derivatives of the general structural formula I STR1 have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, inflammatory diseases including Raynaud's disease and asthma.

Regiospecific functionalization of 1,3-dihydro-2H-benzimidazol-2-one and structurally related cyclic urea derivatives

Methods for selectively protecting one of the degenerate nitrogen atoms of the cyclic urea derivatives 1,3-dihydro-2H-benzimidazol-2-one (6a), 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (11), 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones (20), 1,3-dihydro-

A NOVEL SYNTHESIS OF BENZIMIDAZOLINONES

A new route to N-monosubstituted benzimidazolinones, involving an hetero-oxy Cope rearrangement, consists in the reaction of hydroxamic acids with cyanogen bromide.